Long non-coding RNA HCP5 in cancer.
Clin Chim Acta
; 512: 33-39, 2021 Jan.
Article
em En
| MEDLINE
| ID: mdl-33245911
Cancer remains a major threat to human health worldwide. Long non-coding RNA (lncRNA) comprises a group of single-stranded RNA with lengths longer than 200 bp. LncRNAs are aberrantly expressed and play a variety of roles involving multiple cellular processes in cancer. Histocompatibility leukocyte antigen complex P5 (HCP5), initially reported in 1993, is an important lncRNA located between the MICA and MICB genes in MHC I region. HCP5 is involved many autoimmune diseases as well as malignancies. Abnormal HCP5 expression occurs in many types of cancer and its dysregulation appears closely associated with tumor progression. HCP5 is also involved in anti-tumor drug resistance as well. As such, HCP5 represents a promising biomarker and therapeutic target in cancer. In this review, we summarize recent researches and provide an overview of the role and mechanism of HCP5 in human cancer.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
RNA Longo não Codificante
/
Neoplasias
Limite:
Humans
Idioma:
En
Revista:
Clin Chim Acta
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
China